Glenmark Pharmaceuticals Ltd (GLENMARK) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 65075.51 Cr. Figures below are as reported and are shown with their source and date.
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,556 full-time employees. The firm is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The firm also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The firm has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
Source: finedge · as of 2026-09-29
Last close (₹): 2,198.5
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 16,982.51 | 0.1 | 0 |
| Mar 2025 | 13,321.74 | 1,047.1 | 37.11 |
| Mar 2024 | 11,813.1 | -1,501.67 | -53.22 |
| Mar 2023 | 12,990.11 | 377.4 | 13.38 |
| Mar 2022 | 12,304.9 | 941.71 | 33.37 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Source: nse · as of 2026-10-05
Figures computed 2026-10-23.